Go to Patients & Caregivers Site

Prescribing Information

Answers to frequently asked questions about the Nutropin AQ Pen 10

Questions regarding Nutropin AQ Pen 10 needles

Click questions to see answers.

What if medication is leaking from the needle?

A: If the dose knob is turned past the maximum dose of 4.0 mg for the Nutropin AQ Pen 10, medication will come out of the needle. This could also occur if the plunger is not fully retracted prior to replacing a cartridge.

Does the needle need to be changed every time I use the Nutropin AQ Pen 10?

A: Yes. A new needle must be used for every injection. The needle is sterile only on first use.

What should be done with the needles after an injection is given?

A: The patient/caregiver should dispose of needles in a proper sharps disposal container. Improper disposal of needles and other medical sharps can cause needle-stick injuries, especially for garbage collectors. Advise patients to throw used needles away safely. Needles, sharps, or sharps containers should not be included in household trash. Collection programs for these items are available in many locations throughout the country. The specialty pharmacy (SP) or local health department may also be able to advise patients on disposal of containers.

The Coalition for Safe Community Needle Disposal is a coalition of businesses, community groups, nonprofit organizations, and the government that promotes public awareness and solutions for safe disposal of needles, syringes, and other sharps in the community. The Coalition website provides a searchable database of locations that accept used sharps. Patients can search for locations by visiting www.safeneedledisposal.org/.

Please see additional information about proper needle disposal and how to travel with GH medication.

Is there a specific needle recommendation for the Nutropin AQ Pen 10?

A: It is important to select a needle specific to each patient to enable delivery of growth hormone (GH) to the subcutaneous layer of the skin. The Nutropin AQ Pen 10 kit comes with the BD Ultra-Fine™ Original Pen Needle 29 gauge, 12.7 mm (1/2"). This size enables the needle to get to the correct depth of the subcutaneous tissue and also offers a wide inner diameter so that it’s easier to press the black dose knob and expel medication. To avoid the risk of injecting into muscle, injection technique is important, and a gentle pinch of the skin is required when inserting the needle.

Can the Nutropin AQ Pen 10 be used without the shields?

A: Yes. The Nutropin AQ Pen 10 is fully functional without the shields. The shields are optional to help patients administer their injections.

Back to top

Questions regarding Nutropin AQ Pen 10 cartridges

Click questions to see answers.

Can the Nutropin AQ Pen 10 mg Cartridge be used in the Nutropin AQ Pen 20, and vice versa?

A: No. Even though either cartridge will fit in either pen, the Nutropin AQ Pen 10 mg Cartridge must be used with the Nutropin AQ Pen 10. The Nutropin AQ Pen 20 mg Cartridge must be used with the Nutropin AQ Pen 20. Remind patients to always match their prescribed strength Nutropin AQ Pen Cartridge (10 mg or 20 mg) with the corresponding Pen for that cartridge. Using the wrong cartridge in a pen will cause error in the dose that is delivered to the patient.

How long can the Nutropin AQ Pen 10 and Cartridge stay outside the refrigerator?

A: During use, it is recommended to keep Nutropin products outside of the refrigerator for no longer than 1 hour per day. If Nutropin products are kept outside the refrigerator for longer than one hour, the medication should not be used. Direct patients to call 1 (866) NUTROPIN for additional assistance. When traveling, instruct patients to keep their Nutropin device dry and stored within the appropriate temperature range 2°-8°C (36°-46°F).

What is the maximum dose the Nutropin AQ Pen 10 can deliver in 1 injection?

A: The maximum dose that may be delivered in 1 injection is 4.0 mg for the Nutropin AQ Pen 10. If a patient attempts to dose more than the maximum dose at one time, the drug will either be forced out of the needle and wasted or excess pressure will be placed upon the cartridge.

What if the cartridge window shows an amount that is less than expected or if it seems that excessive medication was wasted in the priming step?

A: The Nutropin AQ Pen 10 is designed to deliver 10 mg in 0.1 mg increments. However, the cartridge window is not exact in its markings. You may be able to help patients anticipate when, at their current dose, the cartridge will be completely used. For example, a 1.0 mg dose in a 10 mg cartridge/pen will deliver 10 doses.

What should be done if there is not enough medication left in the cartridge for a patient's dosing requirements?

A: This should be discussed with the patient's prescriber. He or she may want the patient to administer a partial dose with the medication left in the existing cartridge, then start a new cartridge and administer the remainder of the dose. Or, discard the amount that was not given.

Back to top

Questions regarding proper storage and maintenance of the Nutropin AQ Pen 10

Click questions to see answers.

Where should the Nutropin AQ Pen 10 be stored?

A: A Nutropin AQ Pen 10 should be stored in its case, inside a refrigerator at 2°-8°C (36°-46°F), when a cartridge is inserted. When traveling, the pen case should be stored within the same temperature range. The pen must be KEPT DRY and free from moisture. DO NOT FREEZE.

Nutropin AQ is light sensitive and the vial, cartridges, and Nutropin AQ should be protected from light. Store the vial, cartridges, and Nutropin AQ injection device refrigerated in a dark place when they are not in use.

Why must the medication be kept in the refrigerator?

A: To maintain the potency of Nutropin AQ.

Can the Nutropin AQ Pen 10 be placed in the freezer?

A: No. Freezing will damage the pen and drug.

Is the Nutropin AQ Pen 10 waterproof?

A: No. Exposure to moisture may cause the digital dose display of the Nutropin AQ Pen 10 to malfunction. Do not immerse the Nutropin AQ Pen 10 in water. If the Nutropin AQ Pen 10 is accidentally immersed, remove it from the water and dry it immediately.

How do patients replace their Nutropin AQ Pen 10?

A: The patient needs to call their specialty pharmacy (SP). The SP may need to call the prescriber to authorize a prescription for the pen. If the patient has difficulty with the SP, the Nutropin Hotline number should be called.

What should patients do if they drop the Nutropin AQ Pen 10?

A: If patients drop their Nutropin AQ Pen 10, they should check to see if the cartridge is damaged. They should also check the pen to see that the black dose knob is moving up and down properly and that the digital dose display counter is working. If the pen or cartridge is damaged, the patient should receive a replacement pen.

How long can patients use the Nutropin AQ Pen 10?

A: The Nutropin AQ Pen 10 has a battery that is designed to last approximately 24 months from the time of first use. If patients have a functionality issue with the Pen, direct them to call 1-866-NUTROPIN for additional assistance.

Back to top

Questions regarding the black dose knob of the Nutropin AQ Pen 10

Click questions to see answers.

What if the black dose knob cannot be depressed?

A: A dose must be dialed for the knob to be depressed. The most common reason the black knob cannot be depressed is that the knob may be between clicks. Try turning the dosing knob forward until it clicks into dosing position. If this problem happens when the last dose in the cartridge is dialed, turn the knob backward until it clicks into dosing position. The dosing knob cannot be depressed if the needle is not screwed on properly or is bent or occluded. Remind patients to inspect the needle and change it, if necessary.

Is it possible to turn the black dose knob back if it is dialed past the intended dose?

A: Yes. The black dose knob can be turned backward until the correct number appears in the digital dose display.

Why do I have to rewind the black dose knob on the Nutropin AQ Pen 10 every time a cartridge is replaced?

A: This ensures that the plunger push rod completely resets itself back to the starting position. If this is not done, liquid will come out of the needle when a new cartridge is placed into the pen.

Back to top

Questions regarding the digital dose display of the Nutropin AQ Pen 10

Click questions to see answers.

What does "bt" (blinking or steady) mean in the digital dose display?

A: The battery in the Nutropin AQ Pen 10 is losing its charge. At this time, patients should receive a replacement pen. Batteries typically last 24 months and have a 4-week life from the time the "bt" first appears.

What does it mean when either 3 or 6 bars flash or appear steady on the digital dose display?

A: When this occurs, it means this pen has been used for 2 years and should be replaced. A Nutropin AQ Pen 10 has 4 weeks of life remaining from the time that the flashing bars first appear. At this time, patients should receive a replacement pen.

How does the dose recall function work?

A: Wait at least 2 minutes after the previous injection before pressing the white reset button. The last dose injected will flash in the digital dose display for 5 seconds when the white reset button is depressed, then 0.0 appears.

Back to top

Questions regarding Nutropin AQ Pen 10 injection safety

Click questions to see answers.

What sites should the patient use for injection?

A: The medication should be given subcutaneously as ordered by the prescriber. Suggested injection sites include the back of the upper arms, upper thighs, upper buttocks, and abdomen. It's important that patients alternate injection sites to minimize tissue atrophy (or wasting).

Why is it important to rotate injection sites?

A: Injection site discomfort has been reported. It's important that patients rotate the injection site to avoid tissue atrophy that may result from subcutaneous administration of GH at the same site over a long period of time.

What are the most common adverse events?

A: The most common adverse event is an injection site reaction. Other adverse events may include mild, transient peripheral edema, arthralgias, scoliosis, changes in vision, headache, nausea, carpal tunnel syndrome, and allergic reactions.

Who should the patient contact if he or she experiences a side effect or adverse event?

A: If a patient experiences side effects or an adverse event, instruct them to call the healthcare professional (HCP). They are also encouraged to report this information to the FDA at 1-800-FDA-1088.

If the HCP receives information from a patient that indicates he or she is experiencing an adverse event, what should be done?

A: If the HCP becomes aware of a patient having an adverse event, he or she should call the FDA at 1-800-FDA-1088 or contact Genentech Drug Safety/Adverse Events at 1-888-835-2555.

Back to top

INDICATIONS

Pediatric Patients

Nutropin AQ® [somatropin (rDNA origin) injection] and Nutropin [somatropin (rDNA origin) for injection] are indicated for the long-term treatment of growth failure due to a lack of adequate endogenous GH secretion.

Nutropin AQ and Nutropin are also indicated for the treatment of growth failure associated with chronic renal insufficiency up to the time of renal transplantation. Nutropin AQ and Nutropin therapy should be used in conjunction with optimal management of chronic renal insufficiency.

Nutropin AQ and Nutropin are also indicated for the long-term treatment of short stature associated with Turner syndrome.

Nutropin AQ and Nutropin are also indicated for the long-term treatment of idiopathic short stature, also called non-growth hormone deficient short stature, defined by height SDS ≤-2.25, and associated with growth rates unlikely to permit attainment of adult height in the normal range, in pediatric patients whose epiphyses are not closed and for whom diagnostic evaluation excludes other causes associated with short stature that should be observed or treated by other means.

Adult Patients

Nutropin AQ and Nutropin are indicated for replacement of endogenous GH in adults with GH deficiency who meet either of the following two criteria:

  • Adult-Onset: Patients who have GH deficiency, either alone or associated with multiple hormone deficiencies (hypopituitarism), as a result of pituitary disease, hypothalamic disease, surgery, radiation therapy, or trauma; or
  • Childhood-Onset: Patients who were GH deficient during childhood as a result of congenital, genetic, acquired, or idiopathic causes.

In general, confirmation of the diagnosis of adult GH deficiency in both groups usually requires an appropriate GH stimulation test. However, confirmatory GH stimulation testing may not be required in patients with congenital/genetic GH deficiency or multiple pituitary hormone deficiencies due to organic disease.

IMPORTANT SAFETY INFORMATION

Contraindications

GROWTH HORMONE (GH) SHOULD NOT BE USED IN PATIENTS WITH:

  • Closed epiphyses for pediatric growth promotion
  • Active proliferative or severe non-proliferative diabetic retinopathy
  • Active malignancy
  • Acute critical illness due to complications following open heart surgery, abdominal surgery, or multiple accidental trauma, or those with acute respiratory failure
  • Prader-Willi syndrome who are severely obese or have severe respiratory impairment. Nutropin AQ and Nutropin are not indicated in patients with Prader-Willi syndrome who do not also have a diagnosis of GH deficiency
  • Known sensitivity to benzyl alcohol when using Nutropin reconstituted with Bacteriostatic Water for Injection, USP (benzyl alcohol preserved). For use in newborns, see WARNINGS in full Prescribing Information

Additional Safety Information

  • Nutropin AQ and Nutropin should be prescribed by physicians experienced in the diagnosis and management of patients with pediatric or adult GH deficiency, Turner syndrome (TS), or chronic renal insufficiency (CRI).
  • Patients should be monitored for signs of glucose intolerance. Patients taking antihyperglycemic agents may require dose adjustment when GH therapy is instituted.
  • Patients with preexisting tumors or growth hormone deficiency secondary to an intracranial lesion should be examined routinely for progression or recurrence of the underlying disease process.
  • Intracranial hypertension (IH) with papilledema, visual changes, headache, nausea, and/or vomiting has been reported in a small number of patients treated with GH products.
  • In patients with hypopituitarism (multiple hormone deficiencies), standard hormonal replacement therapy should be monitored closely when GH therapy is administered.
  • Periodic thyroid function tests and thyroid replacement therapy should be initiated or appropriately adjusted when indicated.
  • Injection site discomfort has been reported.
  • Rotate injection site to avoid tissue atrophy that may result from subcutaneous administration of GH at the same site over a long period of time.
  • As with any protein, local or systemic allergic reactions may occur.

Pediatric Patients

  • Slipped capital femoral epiphysis may occur more frequently in patients with endocrine disorders or in patients undergoing rapid growth.
  • Children with growth failure secondary to CRI should be examined periodically for evidence of progression of renal osteodystrophy.
  • Progression of scoliosis can occur in patients who experience rapid growth. Patients with a history of scoliosis who are treated with GH should be monitored for progression of scoliosis.

Adult Patients

  • GH therapy may cause fluid retention.
  • Carpal tunnel syndrome, arthralgia, and other joint disorders have been reported in GH-treated patients.

Drug Interactions

  • Patients on GH therapy, with previously undiagnosed central (secondary) hypoadrenalism, may require glucocorticoid replacement therapy. Patients already on glucocorticoid replacement therapy for previously diagnosed hypoadrenalism may require an increase in their maintenance or stress doses.
  • Glucocorticoid replacement therapy should be carefully adjusted in children with concomitant GH and glucocorticoid deficiency to avoid both hypoadrenalism and an inhibitory effect on growth.
  • Careful monitoring is advisable when GH is given in any combination with agents metabolized by CP450 liver enzymes.
  • In women on oral estrogen replacement, a larger dose of somatropin may be required to achieve the defined treatment goal.

Please see full Prescribing Information for additional Important Safety Information.

The content available from this website is for informational purposes only. Individual results may vary. You may report side effects to the FDA at 1-800-FDA-1088 or to Genentech Drug Safety/Adverse Events at 1-888-835-2555.

Nutropin and Nutropin AQ are registered trademarks; and NuSpin, growingopportunity, and Nutropin GPS are trademarks of Genentech Inc.

Back to top

Important Safety Information

INDICATIONS

Pediatric Patients

Nutropin AQ® [somatropin (rDNA origin) injection] and Nutropin [somatropin (rDNA origin) for injection] are indicated for the long-term treatment of growth failure due to a lack of adequate endogenous GH secretion.

Nutropin AQ and Nutropin are also indicated for the treatment of growth failure associated with chronic renal insufficiency up to the time of renal transplantation. Nutropin AQ and Nutropin therapy should be used in conjunction with optimal management of chronic renal insufficiency.

Nutropin AQ and Nutropin are also indicated for the long-term treatment of short stature associated with Turner syndrome.

Nutropin AQ and Nutropin are also indicated for the long-term treatment of idiopathic short stature, also called non-growth hormone deficient short stature, defined by height SDS ≤-2.25, and associated with growth rates unlikely to permit attainment of adult height in the normal range, in pediatric patients whose epiphyses are not closed and for whom diagnostic evaluation excludes other causes associated with short stature that should be observed or treated by other means.

Adult Patients

Nutropin AQ and Nutropin are indicated for replacement of endogenous GH in adults with GH deficiency who meet either of the following two criteria:

  • Adult-Onset: Patients who have GH deficiency, either alone or associated with multiple hormone deficiencies (hypopituitarism), as a result of pituitary disease, hypothalamic disease, surgery, radiation therapy, or trauma; or
  • Childhood-Onset: Patients who were GH deficient during childhood as a result of congenital, genetic, acquired, or idiopathic causes.

In general, confirmation of the diagnosis of adult GH deficiency in both groups usually requires an appropriate GH stimulation test. However, confirmatory GH stimulation testing may not be required in patients with congenital/genetic GH deficiency or multiple pituitary hormone deficiencies due to organic disease.

IMPORTANT SAFETY INFORMATION

Contraindications

GROWTH HORMONE (GH) SHOULD NOT BE USED IN PATIENTS WITH:

  • Closed epiphyses for pediatric growth promotion
  • Active proliferative or severe non-proliferative diabetic retinopathy
  • Active malignancy
  • Acute critical illness due to complications following open heart surgery, abdominal surgery, or multiple accidental trauma, or those with acute respiratory failure
  • Prader-Willi syndrome who are severely obese or have severe respiratory impairment. Nutropin AQ and Nutropin are not indicated in patients with Prader-Willi syndrome who do not also have a diagnosis of GH deficiency
  • Known sensitivity to benzyl alcohol when using Nutropin reconstituted with Bacteriostatic Water for Injection, USP (benzyl alcohol preserved). For use in newborns, see WARNINGS in full Prescribing Information

Additional Safety Information

  • Nutropin AQ and Nutropin should be prescribed by physicians experienced in the diagnosis and management of patients with pediatric or adult GH deficiency, Turner syndrome (TS), or chronic renal insufficiency (CRI).
  • Patients should be monitored for signs of glucose intolerance. Patients taking antihyperglycemic agents may require dose adjustment when GH therapy is instituted.
  • Patients with preexisting tumors or growth hormone deficiency secondary to an intracranial lesion should be examined routinely for progression or recurrence of the underlying disease process.
  • Intracranial hypertension (IH) with papilledema, visual changes, headache, nausea, and/or vomiting has been reported in a small number of patients treated with GH products.
  • In patients with hypopituitarism (multiple hormone deficiencies), standard hormonal replacement therapy should be monitored closely when GH therapy is administered.
  • Periodic thyroid function tests and thyroid replacement therapy should be initiated or appropriately adjusted when indicated.
  • Injection site discomfort has been reported.
  • Rotate injection site to avoid tissue atrophy that may result from subcutaneous administration of GH at the same site over a long period of time.
  • As with any protein, local or systemic allergic reactions may occur.

Pediatric Patients

  • Slipped capital femoral epiphysis may occur more frequently in patients with endocrine disorders or in patients undergoing rapid growth.
  • Children with growth failure secondary to CRI should be examined periodically for evidence of progression of renal osteodystrophy.
  • Progression of scoliosis can occur in patients who experience rapid growth. Patients with a history of scoliosis who are treated with GH should be monitored for progression of scoliosis.

Adult Patients

  • GH therapy may cause fluid retention.
  • Carpal tunnel syndrome, arthralgia, and other joint disorders have been reported in GH-treated patients.

Drug Interactions

  • Patients on GH therapy, with previously undiagnosed central (secondary) hypoadrenalism, may require glucocorticoid replacement therapy. Patients already on glucocorticoid replacement therapy for previously diagnosed hypoadrenalism may require an increase in their maintenance or stress doses.
  • Glucocorticoid replacement therapy should be carefully adjusted in children with concomitant GH and glucocorticoid deficiency to avoid both hypoadrenalism and an inhibitory effect on growth.
  • Careful monitoring is advisable when GH is given in any combination with agents metabolized by CP450 liver enzymes.
  • In women on oral estrogen replacement, a larger dose of somatropin may be required to achieve the defined treatment goal.

Please see full Prescribing Information for additional Important Safety Information.

View indication and safety information

INDICATIONS

Pediatric Patients

Nutropin AQ® [somatropin (rDNA origin) injection] and Nutropin [somatropin (rDNA origin) for injection] are indicated for the long-term treatment of growth failure due to a lack of adequate endogenous GH secretion.

Nutropin AQ and Nutropin are also indicated for the treatment of growth failure associated with chronic renal insufficiency up to the time of renal transplantation. Nutropin AQ and Nutropin therapy should be used in conjunction with optimal management of chronic renal insufficiency.

Nutropin AQ and Nutropin are also indicated for the long-term treatment of short stature associated with Turner syndrome.

Nutropin AQ and Nutropin are also indicated for the long-term treatment of idiopathic short stature, also called non-growth hormone deficient short stature, defined by height SDS ≤-2.25, and associated with growth rates unlikely to permit attainment of adult height in the normal range, in pediatric patients whose epiphyses are not closed and for whom diagnostic evaluation excludes other causes associated with short stature that should be observed or treated by other means.

Adult Patients

Nutropin AQ and Nutropin are indicated for replacement of endogenous GH in adults with GH deficiency who meet either of the following two criteria:

  • Adult-Onset: Patients who have GH deficiency, either alone or associated with multiple hormone deficiencies (hypopituitarism), as a result of pituitary disease, hypothalamic disease, surgery, radiation therapy, or trauma; or
  • Childhood-Onset: Patients who were GH deficient during childhood as a result of congenital, genetic, acquired, or idiopathic causes.

In general, confirmation of the diagnosis of adult GH deficiency in both groups usually requires an appropriate GH stimulation test. However, confirmatory GH stimulation testing may not be required in patients with congenital/genetic GH deficiency or multiple pituitary hormone deficiencies due to organic disease.

IMPORTANT SAFETY INFORMATION

Contraindications

GROWTH HORMONE (GH) SHOULD NOT BE USED IN PATIENTS WITH:

  • Closed epiphyses for pediatric growth promotion
  • Active proliferative or severe non-proliferative diabetic retinopathy
  • Active malignancy
  • Acute critical illness due to complications following open heart surgery, abdominal surgery, or multiple accidental trauma, or those with acute respiratory failure
  • Prader-Willi syndrome who are severely obese or have severe respiratory impairment. Nutropin AQ and Nutropin are not indicated in patients with Prader-Willi syndrome who do not also have a diagnosis of GH deficiency
  • Known sensitivity to benzyl alcohol when using Nutropin reconstituted with Bacteriostatic Water for Injection, USP (benzyl alcohol preserved). For use in newborns, see WARNINGS in full Prescribing Information

Additional Safety Information

  • Nutropin AQ and Nutropin should be prescribed by physicians experienced in the diagnosis and management of patients with pediatric or adult GH deficiency, Turner syndrome (TS), or chronic renal insufficiency (CRI).
  • Patients should be monitored for signs of glucose intolerance. Patients taking antihyperglycemic agents may require dose adjustment when GH therapy is instituted.
  • Patients with preexisting tumors or growth hormone deficiency secondary to an intracranial lesion should be examined routinely for progression or recurrence of the underlying disease process.
  • Intracranial hypertension (IH) with papilledema, visual changes, headache, nausea, and/or vomiting has been reported in a small number of patients treated with GH products.
  • In patients with hypopituitarism (multiple hormone deficiencies), standard hormonal replacement therapy should be monitored closely when GH therapy is administered.
  • Periodic thyroid function tests and thyroid replacement therapy should be initiated or appropriately adjusted when indicated.
  • Injection site discomfort has been reported.
  • Rotate injection site to avoid tissue atrophy that may result from subcutaneous administration of GH at the same site over a long period of time.
  • As with any protein, local or systemic allergic reactions may occur.

Pediatric Patients

  • Slipped capital femoral epiphysis may occur more frequently in patients with endocrine disorders or in patients undergoing rapid growth.
  • Children with growth failure secondary to CRI should be examined periodically for evidence of progression of renal osteodystrophy.
  • Progression of scoliosis can occur in patients who experience rapid growth. Patients with a history of scoliosis who are treated with GH should be monitored for progression of scoliosis.

Adult Patients

  • GH therapy may cause fluid retention.
  • Carpal tunnel syndrome, arthralgia, and other joint disorders have been reported in GH-treated patients.

Drug Interactions

  • Patients on GH therapy, with previously undiagnosed central (secondary) hypoadrenalism, may require glucocorticoid replacement therapy. Patients already on glucocorticoid replacement therapy for previously diagnosed hypoadrenalism may require an increase in their maintenance or stress doses.
  • Glucocorticoid replacement therapy should be carefully adjusted in children with concomitant GH and glucocorticoid deficiency to avoid both hypoadrenalism and an inhibitory effect on growth.
  • Careful monitoring is advisable when GH is given in any combination with agents metabolized by CP450 liver enzymes.
  • In women on oral estrogen replacement, a larger dose of somatropin may be required to achieve the defined treatment goal.

Please see full Prescribing Information for additional Important Safety Information.

Scroll down to view complete indication and safety information

Close